Since 2016 Dr Begley has been Chief Scientific Officer (CSO) at Akriveia Therapeutics. He advises several biotechnology companies and serves on the Scientific Advisory Board for the Cancer Science Institute of Singapore. Prior to Akriveia, for three years, he served as CSO at TetraLogic Pharmaceuticals, based in Malvern, PA. From 2002-2012, he was Vice-President and Global Head of Hematology/Oncology Research at Amgen, responsible for building, directing and integrating Amgen's five research sites. During this time he became interested in the issue of research integrity and scientific reproducibilty. Before joining Amgen he had over 20 years of clinical experience in medical oncology and hematology. His personal research has focused on regulation of hematopoietic cells and translational clinical trials.  His early studies first described human G-CSF, and in later clinical studies, he first demonstrated that G-CSF-"mobilized" blood stem cells hastened hematopoietic recovery compared with bone marrow transplantation.  This finding revolutionized the approach to clinical hematopoietic cell transplantation. He is Board Certified in Australia as a Medical Oncologist and Hematologist.

has a PhD in cellular and molecular biology, and has received numerous honours and awards, including being elected as the first Foreign Fellow to the American Society of Clincical Investigation in 2000, to the Assocication of American Physicians in 2008, and to the Research "Hall of Fame" at his alma mater, the Royal Melbourne Hospital in 2014.